Home - Intellia Therapeutics

Milton, living with ATTR-CM

Shanna, Oren and Damian, living with HAE Type 1

Nancy, living with ATTR-PN

News Updates

March 21, 2023

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

Learn More

March 2, 2023

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)

Learn More

View all Intellia News Updates

Our Mission

Transforming lives of people with severe diseases

Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development.

Learn About Our Mission

Programs & Pipeline

Each one of us together for patients

We believe our modular approach to selecting our in vivo and ex vivo programs position us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.

View Our Programs

Full-Spectrum Approach

Opening a new era in medicine

We remain at the forefront of genome editing technology with the most advanced CRISPR-based programs in the clinic backed by a world-class collection of emerging tools in development.

View Our Approach

Join Us.

See how you can change life stories with genome editing

Learn More

News Updates

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)

Transforming lives of people with severe diseases

Each one of us together for patients

Opening a new era in medicine

Powered by Juicer

You are leaving the Intellia Therapeutics, Inc. website.

You are leaving the
Intellia Therapeutics, Inc. website.